Organization (Academic)
UNIVERSITY OF SOUTHERN CALIFORNIA
ClinicalTrials.gov lists UNIVERSITY OF SOUTHERN CALIFORNIA as lead sponsor of 789 trials. It has 391 active development programs and 196 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 39 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 45 in 2026 and about 44 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 9 trials are registered to start in 2027 or later.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers UNIVERSITY OF SOUTHERN CALIFORNIA: 789 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (474)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 55 |
| Obesity | 50 |
| Breast Neoplasms | 47 |
| Prostatic Neoplasms | 41 |
| Dementia | 38 |
Showing 5 of 474 disease areas.
Trials by start year as sponsor or collaborator (35)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 9 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 39 |
| 2025 | 41 |
| 2024 | 50 |
| 2023 | 67 |
| 2022 | 61 |
| 2021 | 84 |
| 2020 | 41 |
| 2019 | 58 |
| 2018 | 52 |
| 2017 | 70 |
Showing 10 of 35 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 86 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 519 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (391)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Cefixime 400mg | HIV Infections | Phase 3 | 1 |
| Benzathine Penicillin | Acquired Immunodeficiency Syndrome | Phase 3 | 1 |
| Cefixime 400mg | Acquired Immunodeficiency Syndrome | Phase 3 | 1 |
| Cefixime 400mg | Syphilis | Phase 3 | 1 |
| Benzathine Penicillin | Syphilis | Phase 3 | 1 |
Showing 5 of 391 active programs.
Approved assets (196)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Acetaminophen | 3 |
| Quetiapine | 3 |
| Oxytocin | 3 |
| CEFTRIAXONE | 2 |
| CELECOXIB | 2 |
Showing 5 of 196 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 33% hit target (n=291) | 33% on time (n=264) |
Journals published in (932)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Diabetes care | 43 |
| The New England journal of medicine | 32 |
| Gastrointestinal endoscopy | 29 |
| Contemporary clinical trials | 24 |
| The Cochrane database of systematic reviews | 23 |
Showing 5 of 932 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,611 | 246 | 2025-12-30 |
Financing and grant events (2,788)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-07 | NIH grant | 732,604 | Reporter |
| 2025-12-08 | NIH grant | 418,254 | Reporter |
| 2025-09-30 | NIH grant | 3,599,190 | Reporter |
| 2025-09-24 | NIH grant | 708,397 | Reporter |
| 2025-09-24 | NIH grant | 1,131,640 | Reporter |
Showing 5 of 2,788 events.
Organization relationships (159)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 102 |
| University of California System | Co sponsors trial with | 29 |
| Alzheimer's Therapeutic Research Institute | Co sponsors trial with | 15 |
| Alzheimer's Clinical Trials Consortium | Co sponsors trial with | 7 |
| Mass General Brigham | Co sponsors trial with | 5 |
Showing 5 of 159 relationships.
Latest dated events (5,422)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2028-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 5,422 events.
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| UNIVERSITY OF SOUTHERN CALIFORNIA | Certificate of compliance | Active |
| UNIVERSITY OF SOUTHERN CALIFORNIA | Certificate of waiver | Active |
| UNIVERSITY OF SOUTHERN CALIFORNIA | Certificate of waiver | Active |
Biomarker capability evidence (1,135)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AATF | Trial sponsor | Named in trial inclusion criteria |
| ABCD1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| ACKR1 | Trial collaborator | Named in trial inclusion criteria |
| ACSBG1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 1,135 evidence rows.
Biomarkers this organization publishes on (2,866)
Shown in this order: most publications first.
Showing 5 of 2,866 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.